Biotech Top Losers: TESARO Inc. (NASDAQ:TSRO), Dyax Corp. (NASDAQ:DYAX), Regulus Therapeutics (NASDAQ:RGLS), Cara Therapeutics (NASDAQ:CARA)

Tesaro Inc. (NASDAQ:TSRO) announced Thursday morning that it has entered into an exclusive, worldwide license agreement and immuno-oncology antibody collaboration with AnaptysBio Inc. TESARO Inc. (NASDAQ:TSRO) stock performance was -5.40% in last session and finished the day at $36.76. Traded volume was 732,104.00 shares in the last session and the average volume of the stock remained 469,070.00 shares. TESARO Inc. (NASDAQ:TSRO) insider ownership is 21.88%. … Continue reading Biotech Top Losers: TESARO Inc. (NASDAQ:TSRO), Dyax Corp. (NASDAQ:DYAX), Regulus Therapeutics (NASDAQ:RGLS), Cara Therapeutics (NASDAQ:CARA)

Biotech Top Gainer: Ariad Pharmaceuticals (NASDAQ:ARIA), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN), Agenus Inc. (NASDAQ:AGEN)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 8.79% in last session and finished the day at $8.17. Traded volume was 18.32 million shares in the last session and the average volume of the stock remained 16.55 million … Continue reading Biotech Top Gainer: Ariad Pharmaceuticals (NASDAQ:ARIA), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN), Agenus Inc. (NASDAQ:AGEN)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares … Continue reading Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume … Continue reading Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases announced that Dan Mitchell has been appointed to the Company’s Board of Directors. Arca Biopharma Inc. (NASDAQ:ABIO) stock performance was -2.31% in last session and finished the day at $2.11. Traded volume was 3.15 million shares in the last session and the average volume of the stock remained 862,287.00 shares. The beta … Continue reading Biotech Most Volatile: Arca Biopharma (NASDAQ:ABIO), Galena Biopharma (NASDAQ:GALE), Progenics Pharmaceuticals (NASDAQ:PGNX), AVEO Pharmaceuticals (NASDAQ:AVEO)

BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings data on Thursday. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.17 by $0.08, Stock Ratings Network.com reports. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 1.56% in last session and finished the day at $26.72. Traded volume was 32,149.00 shares in the last session and the average volume of the stock … Continue reading Biotech Stocks Touching New Highs: BioSpecifics Technologies (NASDAQ:BSTC), NanoString Technologies (NASDAQ:NSTG), Celladon (NASDAQ:CLDN), Receptos (NASDAQ:RCPT)